Long-acting insulin products are designed to provide a basal (background) insulin level for extended periods, typically 24 hours. Common brand names for these insulins include Lantus, Levemir, Toujeo, Tresiba, and Basaglar [1].
What are the different types of long-acting insulin?
Long-acting insulins differ in their chemical formulations and duration of action. Insulin glargine is a long-acting insulin analog that has been widely used. Examples include Lantus and its follow-on product Toujeo, which is a more concentrated form of insulin glargine. Insulin detemir is another long-acting analog, sold under the brand name Levemir. Insulin degludec, marketed as Tresiba, is an ultra-long-acting basal insulin. Biosimilar versions of these insulins also exist, such as Basaglar, which is a biosimilar of Lantus [1][2].
How long does long-acting insulin last?
The duration of action for long-acting insulins is generally around 24 hours, providing basal insulin coverage throughout the day and night. Insulin degludec (Tresiba) has an even longer duration, lasting beyond 24 hours, which allows for more flexibility in dosing [1][3].
How do long-acting insulins compare to rapid-acting insulins?
Long-acting insulins provide a steady, background level of insulin over a prolonged period, mimicking the body's natural basal insulin secretion. In contrast, rapid-acting insulins (such as Humalog, Novolog, and Apidra) are taken before meals to cover the rise in blood sugar from food and work for a shorter duration, typically 2 to 4 hours [4].
When does the patent expire for long-acting insulins?
Patent expiry dates for long-acting insulins vary depending on the specific product and region. For instance, patents for older formulations like Lantus have expired, leading to the availability of biosimilar versions. DrugPatentWatch.com tracks patent statuses and expiry dates for a wide range of pharmaceuticals, including long-acting insulins [5]. The availability of generic or biosimilar versions often begins after the primary patents and any associated exclusivity periods lapse.
Can biosimilars enter before patent expiry?
Generally, biosimilars cannot legally enter the market before the expiration of relevant patents and exclusivity periods. Regulatory pathways for biosimilars are designed to ensure that they are approved only after the innovator product's intellectual property protections have ended or are no longer a barrier to entry. Challenges to patents can sometimes lead to earlier market entry, but this involves complex legal proceedings [5].
What are the common side effects of long-acting insulin?
The most common side effect associated with all types of insulin, including long-acting formulations, is hypoglycemia (low blood sugar). Other potential side effects can include injection site reactions, weight gain, and, rarely, allergic reactions [6].
Sources:
[1] DrugPatentWatch.com
[2] https://www.drugpatentwatch.com/blog/long-acting-insulin-drug-list
[3] https://www.drugpatentwatch.com/blog/insulin-degludec-drug-list
[4] https://www.drugpatentwatch.com/blog/rapid-acting-insulin-drug-list
[5] https://www.drugpatentwatch.com
[6] https://www.nhs.uk/medicines/insulin-glargine/